Oxford Drug Design

Oxford Drug Design is an Oxford biotech developing small molecule therapeutics using an integrated platform combining aminoacyl-tRNA synthetase biology with proprietary generative AI and machine learning.

The platform provides structural biology knowledge, crystallographic data, and novel chemotypes targeting tRNA synthetase enzymes implicated in cancer and infectious disease.

Generative molecular design enables systematic exploration of drug candidate space. Primary pipeline focus is oncology, with additional programmes in antimicrobial resistance.